Simple and Elegant...While we wait....
PressRelease April 5,2024.
Dr.Arkady Mandel said'' TLT cancer vaccine technology represent a significant opportunity for patients diagnosed with blood-related cancer, which are difficult if not impossible to treat.
PressRelease April 9,2024...
TLT said...
''The vaccine methodology is quite simple and elegant(elegant= a scientific solution to a problem, pleasingly ingenious and simple), a sample of the patient's cancer is obtained, whether solid or blood-based, and subsequently treated with TLT-PDC that is then activated with light or X-rays. The wholly-inactivated cancer,with antigen intact,is then injected back into the patient intravenously with the antigens,now programming the patients immune system to recognise, attack and destroy the designated cancer''.
In short...
TLT has a vaccine technology that could treat cancer patients that are difficult if not impossible to treat,and to top it off,TLT cancer vaccine is easy to produce and easy to administer to a cancer patient.
Now, try to imagine a big Pharma reading about TLT cancer vaccine tech, and trying to place a $value on such a simple and elegant solution for difficult if not impossile to treat cancer patients.
First let's get BTD and the money deal that will come with it.